Clinical Research Directory

Inclusion Criteria: Patients with heterozygous familial hypercholesterolemia : 1. Aged between 35 and 60. 2. Having undergone CCTA at least 5 years ago exclusively at the same imaging center (ICT de la Pitié Salpetrière): * Included in the FH-CALC study * Or as part of care between 2018 and 2022 And * For the protected group: absence of coronary stenosis (CADRADS 0) * For the unprotected group: presence of coronary stenosis (CADRDADS ≥ 1) 3. Patient asymptomatic for exertional chest pain at the time of CCTA 4. Clinical examination performed 5. Beneficiary of a social protection scheme or entitled person (excluding AME) 6. Patient informed and consent form signed Exclusion Criteria: 1. Patient under guardianship, or unable to give consent 2. Pregnancy, breast-feeding, women of childbearing age in the absence of effective contraception 3. Technical contraindication: waist \> 70 cm, weight \> 250 kg 4. Renal insufficiency (LC\<60) 5. Unbalanced diabetes when acquiring coronary angioscanner between 2018 and 2022. 6. Personal history of cardiovascular disease and myocardial infarction at the time of CCTA 7. Simultaneous participation in other interventional research involving the human body, or period of exclusion following previous research involving the human body still in progress. 8. Contraindication to iodinated contrast media 9. Contraindication to esmolol and/or atenolol 10. Patient having already had an adverse event (AE) during the acquisition of coronary angioscanner between 2018 and 2022.